ImmuPharma (LON:IMM) Stock Price Up 27.6% – Still a Buy?

ImmuPharma plc (LON:IMMGet Free Report)’s share price rose 27.6% on Friday . The stock traded as high as GBX 3.60 ($0.04) and last traded at GBX 3.35 ($0.04). Approximately 8,992,934 shares traded hands during trading, a decline of 61% from the average daily volume of 23,308,711 shares. The stock had previously closed at GBX 2.63 ($0.03).

ImmuPharma Trading Up 27.6 %

The business’s fifty day moving average price is GBX 1.56 and its 200-day moving average price is GBX 1.68. The company has a market capitalization of £13.95 million, a P/E ratio of -335.00 and a beta of 1.53.

ImmuPharma Company Profile

(Get Free Report)

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

See Also

Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.